EGFR and neoplasm: Due to increasing research on molecular tumor markers and NSCLC-driven genes, rapid development of the EGFR targeted therapy, also known as EGFR tyrosine kinase inhibitors (EGFR-TKIs), could effectively control NSCLC progression [7, 8].